MAFSecukinumab (Cosentyx) Injection, Prefilled Pen 150 mg/mL
Additional clinical criteria applies
1) Treatment of adult patients with ankylosing spondylitis
2)...
MAFSecukinumab (Cosentyx) Injection, Prefilled Pen 150 mg/mL
Additional clinical criteria applies
1) Treatment of adult patients with ankylosing spondylitis
2) Treatment of adult patients with psoriatic arthritis with axial involvement
3) Treatment of adult patients with psoriatic arthritis with peripheral involvement
4) Treatment of adult patients with chronic plaque psoriasis
5) Treatment of children and adolescents aged 6 years and above with chronic plaque psoriasis
6) Treatment of adult patients with non-radiographic axial spondyloarthritis (axSpA).
MAFSecukinumab (Cosentyx) Injection, Prefilled Pen 300 mg/2 mL
Additional clinical criteria applies
1) Treatment of adult patients with ankylosing spondylitis
2)...
MAFSecukinumab (Cosentyx) Injection, Prefilled Pen 300 mg/2 mL
Additional clinical criteria applies
1) Treatment of adult patients with ankylosing spondylitis
2) Treatment of adult patients with psoriatic arthritis with axial involvement
3) Treatment of adult patients with psoriatic arthritis with peripheral involvement
4) Treatment of adult patients with chronic plaque psoriasis
5) Treatment of children and adolescents aged 6 years and above with chronic plaque psoriasis
MAFSecukinumab (Cosentyx) Prefilled Syringe 75 mg/0.5 mL
Additional clinical criteria applies
Treatment of children and adolescents aged 6 years and above ...
MAFSecukinumab (Cosentyx) Prefilled Syringe 75 mg/0.5 mL
Additional clinical criteria applies
Treatment of children and adolescents aged 6 years and above with chronic plaque psoriasis